OC

Serial Number 79213106
Registration 5466730
739

Registration Progress

Application Filed
Feb 6, 2017
Under Examination
Approved for Publication
Feb 27, 2018
Published for Opposition
Feb 27, 2018
Registered
May 15, 2018

Trademark Image

OC

Basic Information

Serial Number
79213106
Registration Number
5466730
Filing Date
February 6, 2017
Registration Date
May 15, 2018
Published for Opposition
February 27, 2018
Drawing Code
3

Status Summary

Current Status
Active
Status Code
739
Status Date
Jun 13, 2025
Registration
Registered
Classes
005 042

Rights Holder

ANEMOCYTE S.R.L.

16
Address
Via Roberto Lepetit, 34
GERENZANO (VA) I-21040
IT

Ownership History

ANEMOCYTE S.R.L.

Original Applicant
16
IT

ANEMOCYTE S.R.L.

Owner at Publication
16
IT

ANEMOCYTE S.R.L.

Original Registrant
16
GERENZANO (VA) IT

Legal Representation

Attorney
Brian A. Tollefson

USPTO Deadlines

Next Deadline
1021 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2018-05-15)
Due Date
May 15, 2028
Grace Period Ends
November 15, 2028

Application History

45 events
Date Code Type Description Documents
Jun 13, 2025 NA75 E NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED Loading...
Jun 13, 2025 C75A O REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. Loading...
Jun 5, 2025 EROP I TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED Loading...
Dec 18, 2024 PR75 O POST REGISTRATION ACTION MAILED - SEC. 71 & 15 Loading...
Dec 16, 2024 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
May 14, 2024 ES75 I TEAS SECTION 71 & 15 RECEIVED Loading...
May 15, 2023 REM3 E COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Loading...
Oct 24, 2022 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Oct 24, 2022 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Oct 24, 2022 ECDR I TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Loading...
Oct 24, 2022 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Oct 24, 2022 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Oct 24, 2022 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Oct 24, 2022 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Apr 9, 2021 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
Sep 15, 2018 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Aug 24, 2018 FIMP P FINAL DISPOSITION PROCESSED Loading...
Aug 24, 2018 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Aug 15, 2018 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
May 15, 2018 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Feb 27, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 27, 2018 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 22, 2018 ADCH M CHANGE OF NAME/ADDRESS REC'D FROM IB Loading...
Feb 7, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 25, 2018 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 25, 2018 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jan 25, 2018 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Jan 25, 2018 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jan 25, 2018 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jan 22, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 22, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 18, 2018 ALIE A ASSIGNED TO LIE Loading...
Jan 3, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Oct 20, 2017 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Oct 20, 2017 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Aug 18, 2017 RFNT P REFUSAL PROCESSED BY IB Loading...
Aug 3, 2017 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Aug 3, 2017 RFRR P REFUSAL PROCESSED BY MPU Loading...
Aug 1, 2017 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Aug 1, 2017 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Jul 31, 2017 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 28, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
Jul 28, 2017 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 27, 2017 LIMI I LIMITATION FROM ORIGINAL APPLICATION ENTERED Loading...
Jul 27, 2017 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Pharmaceutical [ and veterinary ] preparations, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues, all ] for use in human [ and veterinary ] medicine; Chemical preparations for pharmaceutical or medical purposes, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues, all for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Prescription and non-prescription ] medicines, [ namely, pills, tablets, capsules, caplets, liquid drops, sachets, and ] pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; ] Biological preparations for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; ] Biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues, all for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Diagnostic preparations for medical purposes; ] Medicines for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; Organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; ] Biological reagents for medical use; Medicinal preparations based on cells and genes, namely, [ somatic cells, ] genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; [ Medicinal preparations based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; Products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, natural killer cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, ] products for gene therapy, namely, [ genetically modified cells, viral vectors, ] nucleic acids; [ Gene therapy products, namely, genetically engineered tissues for transplant purposes; Medicaments, namely, cells and tissues that have been subjected to extensive manipulation, to help assist with the regeneration of ligament and tendon fibers; ] Preparations for personalized medicine made of [ autologous cells or proteins or ] nucleic acids derived from individual genomic sequences; [ Preparations made up of cells for medical or clinical use; ] Preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes [ ; Preparations made up of tissues, namely, biological tissue cultures for medical purposes; Vaccines; Recombinant proteins supplements; Therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy ]
Class 042
Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; Research and development in the pharmaceutical and biotechnology fields; Research and development in the field of micro-organisms and cells; Research and development in the field of biochemistry; Scientific research and development in the field of biology; Research and development in the field of diagnostic preparations; Services of medical laboratories; Compiling medical information and data for research and development purposes in the medical and veterinary fields; Scientific and technological services, namely, scientific research and technical writing; Scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; Consultancy to ensure compliance with quality standards, the design and validation of manufacturing processes in the field of biology

Additional Information

Design Mark
The mark consists of two side-by-side, touching circles, in which the circle on the right has two breaks. The circle on the left is light blue on the left, blue in the middle, and green on the right. The broken circle on the right is three quarters green and the separated one quarter portion is light gray.
Color Claim
The color(s) light blue, blue, green and light grey is/are claimed as a feature of the mark.

Classification

International Classes
005 042